Last year, Congress passed the Mainstreaming Addiction Treatment (MAT) Act, seeking to expand access to buprenorphine, a proven treatment for opioid use disorder. However, a recent proposal by the Drug Enforcement Administration threatens to undermine Congress' intention. Now, some members of Congress appear ready to push back.
Policy & Ethics
The U.S. Government doesn't want to hear the message: The Centers for Disease Control and the Veterans Administration published practice guidelines on the prescription of opioid pain relievers in 2022 that they knew were unsupported by science and harmful to public health. The Department of Health and Human Services is stone-walling repeated demands for a senior staff review of these issues.
Either of two phenomena may be at work -- the "placebo effect" or the "post hoc, ergo propter hoc" (after this, therefore because of this) fallacy.
Roadside drug tests are unreliable, so why are they so widely used in the U.S.? Meanwhile, researchers who make "health disparities" the focus of their work sometimes misrepresent their results. Here's a textbook example from a study that used pulse oximetry to measure disparities in COVID-19 treatment.
Cato Institute's Dr. Jeffrey Singer, in an opinion piece in USA Today, writes that for years we've been buying and using an ineffective, potentially dangerous decongestant. Why? Just another futile attempt to restrict access to illegal drugs, in this case, methamphetamine. With phenylephrine off pharmacy shelves, the ACSH advisor explores what this means.
The FDA seems intent on imposing a ban on menthol cigarettes and cigars, despite evidence from Europe that it only fuels a black market. And despite evidence in the U.S. that it may worsen inequities in law enforcement.
“Last month, California lawmakers passed a bill that would decriminalize the personal possession of small amounts of a few plant-based psychedelics. This raised hopes that this could be the first of many reforms to unlock the therapeutic potential of psychedelics. Unfortunately, Governor Newsom vetoed the bill, citing reasons that can only be characterized as specious.”
It's 1980 and Queen released a huge, timeless hit, "Another One Bites the Dust." Imagine if someone wrote a parody about today's "fake" opioid crisis and put it to music. Wouldn't that be entertaining? Imagine no longer. Here it is.
Everyone should have a primary care provider (PCP), but not everyone does. There are myriad reasons why: some choose not to go to the doctor (hello, young people); some can’t afford care; others may live in provider “deserts” such as rural areas. Whatever the reason, a growing movement exists to expand who can act as a PCP. Chiropractors have been a part of this expansion, but is that wise?
Morbidity and Mortality (M&M) conferences are routinely held by hospitals to evaluate individual patient care, discuss/dissect interesting cases, and analyze adverse outcomes. It aims to teach, learn, and modify medical/nursing behaviors where appropriate so as to improve patient care. Meetings are confidential to facilitate frank discussion. But a recent case portends evisceration of the confidentiality rule. Plaintiffs are cheering. Defendant-doctors, not. Who’s right?
The New York Times devoted nearly a full page in the business section to “emissions.” Emissions of what? Presumably, CO2, which was not explicitly mentioned, nor were methane, black carbon, or other greenhouse agents. The U.S. has focused – even obsessed – on CO2, and we act as if the nation was the chief player on the planet. That makes us feel good and even self-satisfied in assuming that our diligence is helping to save the planet. But is it?
The BS that has been put out by the anti-opioid zealots has been more than bad enough. Then Senator Joe Manchin joined the fray, taking it to a new level. Disgusting.